{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:59:25Z","timestamp":1789761565435,"version":"4.0.1"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"am","delay-in-days":294,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.cyto.2021.155645","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T03:22:05Z","timestamp":1626924125000},"page":"155645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["An update on the pathogenic role of IL-6 in rheumatic diseases"],"prefix":"10.1016","volume":"146","author":[{"given":"Yuko","family":"Kaneko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cyto.2021.155645_b0005","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.4049\/jimmunol.111.4.1194","article-title":"Regulation of antibody response in vitro. VII. Enhancing soluble factors for IgG and IgE antibody response","volume":"111","author":"Kishimoto","year":"1973","journal-title":"J Immunol."},{"issue":"6092","key":"10.1016\/j.cyto.2021.155645_b0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/324073a0","article-title":"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin","volume":"324","author":"Hirano","year":"1986","journal-title":"Nature"},{"issue":"4867","key":"10.1016\/j.cyto.2021.155645_b0015","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.3136546","article-title":"Cloning and expression of the human interleukin-6 (BSF-2\/IFN beta 2) receptor","volume":"241","author":"Yamasaki","year":"1988","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.cyto.2021.155645_b0020","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/0092-8674(90)90411-7","article-title":"Molecular cloning and expression of an IL-6 signal transducer, gp130","volume":"63","author":"Hibi","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.cyto.2021.155645_b0025","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol."},{"issue":"5","key":"10.1016\/j.cyto.2021.155645_b0030","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/annrheumdis-2016-210324","article-title":"Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications","volume":"76","author":"Ombrello","year":"2017","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"10.1016\/j.cyto.2021.155645_b0035","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/art.39332","volume":"68","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"10.1016\/j.cyto.2021.155645_b0040","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1002\/art.22175","article-title":"Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system","volume":"54","author":"De Benedetti","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.cyto.2021.155645_b0045","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1002\/art.39295","article-title":"Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome","volume":"67","author":"Cifaldi","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"10.1016\/j.cyto.2021.155645_b0050","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1172\/JCI117206","article-title":"Serum soluble interleukin 6 (IL-6) receptor and IL-6\/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis","volume":"93","author":"De Benedetti","year":"1994","journal-title":"J Clin Invest."},{"issue":"7","key":"10.1016\/j.cyto.2021.155645_b0055","first-page":"1670","article-title":"Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis","volume":"28","author":"Pignatti","year":"2001","journal-title":"J Rheumatol."},{"issue":"11","key":"10.1016\/j.cyto.2021.155645_b0060","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood.V87.11.4824.bloodjournal87114824","article-title":"Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis","volume":"87","author":"Cazzola","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155645_b0065","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/art.20944","article-title":"Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis","volume":"3","author":"Yokota","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"9617","key":"10.1016\/j.cyto.2021.155645_b0070","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2021.155645_b0075","doi-asserted-by":"crossref","unstructured":"De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012367(25):2385-95.","DOI":"10.1056\/NEJMoa1112802"},{"issue":"4","key":"10.1016\/j.cyto.2021.155645_b0080","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/annrheumdis-2012-202310","article-title":"Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan","volume":"72","author":"Yokota","year":"2013","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"10.1016\/j.cyto.2021.155645_b0085","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/art.38984","article-title":"Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial","volume":"67","author":"De Benedetti","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cyto.2021.155645_b0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/095952879708000106","article-title":"On a Form of chronic Joint Disease in Children","volume":"80","author":"Still","year":"1897","journal-title":"Med Chir Trans."},{"issue":"2","key":"10.1016\/j.cyto.2021.155645_b0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/ard.30.2.121","article-title":"Still disease in adult","volume":"30","author":"Bywaters","year":"1971","journal-title":"Ann Rheum Dis."},{"issue":"1\u20132","key":"10.1016\/j.cyto.2021.155645_b0100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12026-014-8561-9","article-title":"Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart","volume":"61","author":"Jamilloux","year":"2015","journal-title":"Immunol Res."},{"key":"10.1016\/j.cyto.2021.155645_b0105","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","article-title":"Cytokine profile in adult-onset Still's disease: Comparison with systemic juvenile idiopathic arthritis","volume":"169","author":"Inoue","year":"2016","journal-title":"Clin Immunol."},{"issue":"12","key":"10.1016\/j.cyto.2021.155645_b0110","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.cyto.2021.155645_b0115","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1136\/annrheumdis-2011-200795","article-title":"Distribution of arterial lesions in Takayasu\u2019s arteritis and giant cell arteritis","volume":"71","author":"Grayson","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.cyto.2021.155645_b0120","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MD.0b013e3181af70c1","article-title":"Takayasu arteritis and giant cell arteritis: A spectrum within the same disease?","volume":"88","author":"Maksimowicz-McKinnon","year":"2009","journal-title":"Medicine"},{"issue":"10","key":"10.1016\/j.cyto.2021.155645_b0125","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11926-020-00948-x","article-title":"Pathogenesis of Giant Cell Arteritis and Takayasu Arteritis-Similarities and Differences","volume":"22","author":"Watanabe","year":"2020","journal-title":"Curr Rheumatol Rep."},{"issue":"3","key":"10.1016\/j.cyto.2021.155645_b0130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/WNO.0b013e318268aa9b","article-title":"The immunopathology of giant cell arteritis: diagnostic and therapeutic implications","volume":"32","author":"Weyand","year":"2012","journal-title":"J Neuroophthalmol."},{"key":"10.1016\/j.cyto.2021.155645_b0135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.carpath.2018.01.004","article-title":"IL-6 expression is correlated with increased T-cell proliferation and survival in the arterial wall in giant cell arteritis","volume":"33","author":"Manku","year":"2018","journal-title":"Cardiovasc Pathol."},{"issue":"6","key":"10.1016\/j.cyto.2021.155645_b0140","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/rheumatology\/29.6.456","article-title":"Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis","volume":"29","author":"Dasgupta","year":"1990","journal-title":"Br J Rheumatol."},{"issue":"5","key":"10.1016\/j.cyto.2021.155645_b0145","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/annrheumdis-2016-210070","article-title":"An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy","volume":"76","author":"Miyabe","year":"2017","journal-title":"Ann Rheum Dis."},{"issue":"10031","key":"10.1016\/j.cyto.2021.155645_b0150","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cyto.2021.155645_b0155","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of Tocilizumab in Giant-Cell Arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.cyto.2021.155645_b0160","first-page":"506","article-title":"Pathogenesis of Takayasu's arteritis","volume":"14","author":"Noris","year":"2001","journal-title":"J Nephrol."},{"issue":"2","key":"10.1016\/j.cyto.2021.155645_b0165","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1172\/JCI117029","article-title":"Perforin-secreting killer cell infiltration and expression of a 65-kD heat-shock protein in aortic tissue of patients with Takayasu's arteritis","volume":"93","author":"Seko","year":"1994","journal-title":"J Clin Invest."},{"issue":"5","key":"10.1016\/j.cyto.2021.155645_b0170","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/art.39037","article-title":"Th1 and Th17 cytokines drive inflammation in Takayasu arteritis","volume":"67","author":"Saadoun","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"10.1016\/j.cyto.2021.155645_b0175","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.humimm.2006.06.003","article-title":"Interleukin (IL)-12, IL-2, and IL-6 gene polymorphisms in Takayasu's arteritis from Turkey","volume":"67","author":"Saruhan-Direskeneli","year":"2006","journal-title":"Hum Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2021.155645_b0180","first-page":"102","article-title":"Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study","volume":"Suppl 103","author":"Pulsatelli","year":"2017","journal-title":"Clin Exp Rheumatol."},{"issue":"5","key":"10.1016\/j.cyto.2021.155645_b0185","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/rheumatology\/kei266","article-title":"Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis","volume":"45","author":"Park","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.cyto.2021.155645_b0190","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","article-title":"Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)","volume":"77","author":"Nakaoka","year":"2018","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"10.1016\/j.cyto.2021.155645_b0195","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/art.34647","article-title":"Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.cyto.2021.155645_b0200","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1072-4","article-title":"Circadian variations in clinical symptoms and concentrations of inflammatory cytokines, melatonin, and cortisol in polymyalgia rheumatica before and during prednisolone treatment: a controlled, observational, clinical experimental study","volume":"18","author":"Galbo","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.cyto.2021.155645_b0205","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/ard.2008.103663","article-title":"Circulating cytokines in active polymyalgia rheumatica","volume":"69","author":"Alvarez-Rodr\u00edguez","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.cyto.2021.155645_b0210","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.39740","article-title":"Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica","volume":"68","author":"Lally","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cyto.2021.155645_b0215","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03263715."},{"key":"10.1016\/j.cyto.2021.155645_b0220","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03600818."},{"key":"10.1016\/j.cyto.2021.155645_b0225","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semarthrit.2015.02.002","article-title":"Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab","volume":"45","author":"Berti","year":"2015","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.cyto.2021.155645_b0230","first-page":"433","article-title":"In vitro up-regulation of E-selectin and induction of interleukin-6 in endothelial cells by autoantibodies in Wegener's granulomatosis and microscopic polyangiitis","volume":"17","author":"Muller Kobold","year":"1999","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.cyto.2021.155645_b0235","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/art.10384","article-title":"In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase","volume":"46","author":"Popa","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2021.155645_b0240","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/1348-0421.12080","volume":"57","author":"Nagao","year":"2013","journal-title":"Microbiol Immunol."},{"key":"10.1016\/j.cyto.2021.155645_b0245","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/978-1-4757-9182-2_56","article-title":"Pro- and anti-inflammatory cytokines in primary systemic vasculitis","volume":"336","author":"Kekow","year":"1993","journal-title":"Adv Exp Med Biol."},{"key":"10.1016\/j.cyto.2021.155645_b0250","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/09629350400003100","article-title":"Circulating cytokine profile in anti-neutrophilic cytoplasmatic autoantibody-associated vasculitis: prediction of outcome?","volume":"13","author":"Ohlsson","year":"2004","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.cyto.2021.155645_b0255","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s10067-017-3752-0","article-title":"Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review","volume":"36","author":"Sakai","year":"2017","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.cyto.2021.155645_b0260","doi-asserted-by":"crossref","unstructured":"Sumida K, Ubara Y, Suwabe T, Hayami N, Hiramatsu R, Hasegawa E, Yamanouchi54, Hoshino J, Sawa N, Takemoto F, Takaichi K, Ohashi K. Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody. Rheumatology (Oxford). 2011;50:1928-30.","DOI":"10.1093\/rheumatology\/ker222"},{"key":"10.1016\/j.cyto.2021.155645_b0265","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3109\/14397595.2015.1021138","article-title":"Corticosteroid- and cyclophosphamide-free treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis using tocilizumab","volume":"25","author":"Sakai","year":"2015","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.cyto.2021.155645_b0270","unstructured":"the Clinical Trial Registry of Japan Medical Association. https:\/\/dbcentre3.jmacct.med.or.jp\/jmactr\/App\/JMACTRS06\/JMACTRS06.aspx?seqno=7416."},{"key":"10.1016\/j.cyto.2021.155645_b0275","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.autrev.2011.11.026","article-title":"New insights into the pathogenesis of Behcet\u2019s disease","volume":"11","author":"Pineton de Chambrun","year":"2012","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.cyto.2021.155645_b0280","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0923-1811(95)00439-4","article-title":"Interleukin-6 (IL-6) in patients with Beh\u00e7et's disease","volume":"11","author":"Yamakawa","year":"1996","journal-title":"J Dermatol Sci."},{"key":"10.1016\/j.cyto.2021.155645_b0285","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1006\/clin.1996.4268","article-title":"Cerebrospinal fluid interleukin-6 in progressive Neuro-Beh\u00e7et's syndrome","volume":"82","author":"Hirohata","year":"1997","journal-title":"Clin Immunol Immunopathol."},{"key":"10.1016\/j.cyto.2021.155645_b0290","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cyto.2008.10.007","article-title":"Interleukin-6 in neuro-Beh\u00e7et's disease: association with disease subsets and long-term outcome","volume":"44","author":"Akman-Demir","year":"2008","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2021.155645_b0295","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.semarthrit.2020.05.017","article-title":"Effectiveness of tocilizumab in Behcet's disease: A systematic literature review","volume":"50","author":"Akiyama","year":"2020","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.cyto.2021.155645_b0300","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01693653."},{"key":"10.1016\/j.cyto.2021.155645_b0305","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03554161."},{"key":"10.1016\/j.cyto.2021.155645_b0310","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00002281-200401000-00011","article-title":"Relapsing polychondritis","volume":"16","author":"Kent","year":"2004","journal-title":"Curr Opin Rheumatol."},{"key":"10.1016\/j.cyto.2021.155645_b0315","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJM197811302992202","article-title":"Antibodies to type II collagen in relapsing polychondritis","volume":"299","author":"Foidart","year":"1978","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cyto.2021.155645_b0320","first-page":"1419","article-title":"Preferential cellular and humoral immune reactivities to native and denatured collagen types IX and XI in a patient with fatal relapsing polychondritis","volume":"20","author":"Alsalameh","year":"1993","journal-title":"J Rheumatol."},{"key":"10.1016\/j.cyto.2021.155645_b0325","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/ard.40.5.473","article-title":"Autoantibodies to cartilage and type II collagen in relapsing polychondritis and other rheumatic diseases","volume":"40","author":"Ebringer","year":"1981","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.cyto.2021.155645_b0330","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1002\/art.20613","article-title":"Serum cytokine profiles in relapsing polychondritis suggest monocyte\/macrophage activation","volume":"50","author":"Stabler","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2021.155645_b0335","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/art.1780270113","article-title":"Cytokine modulation of chondrocyte proteinase release","volume":"27","author":"Herman","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2021.155645_b0340","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/322547a0","article-title":"Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage","volume":"322","author":"Saklatvala","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.cyto.2021.155645_b0345","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/art.1780240610","article-title":"Lymphokine-mediated suppression of chondrocyte glycosaminoglycan and protein synthesis","volume":"24","author":"Herman","year":"1981","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2021.155645_b0350","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3899\/jrheum.120381","article-title":"Refractory relapsing polychondritis treated with serial success with interleukin 6 receptor blockade","volume":"40","author":"Wallace","year":"2013","journal-title":"J Rheumatol."},{"key":"10.1016\/j.cyto.2021.155645_b0355","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/rheumatology\/ken468","article-title":"Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis","volume":"48","author":"Kawai","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2021.155645_b0360","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/09273948.2020.1763405","article-title":"Sustained Remission with Tocilizumab in Refractory Relapsing Polychondritis with Ocular Involvement: A Case Series","volume":"29","author":"Farhat","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"10.1016\/j.cyto.2021.155645_b0365","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/rheumatology\/ker451","article-title":"Sustained response to tocilizumab, anti-IL-6 antibody, following anti-TNF-\u03b1 failure in a patient with relapsing polychondritis complicated by aortitis","volume":"51","author":"Narshi","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2021.155645_b0370","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/03009742.2016.1275774","article-title":"Successful treatment with tocilizumab for refractory scleritis associated with relapsing polychondritis","volume":"46","author":"Shimizu","year":"2017","journal-title":"Scand J Rheumatol."},{"issue":"1","key":"10.1016\/j.cyto.2021.155645_b0375","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ajpath.2011.09.013","article-title":"Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma","volume":"180","author":"Kitaba","year":"2012","journal-title":"Am J Pathol."},{"issue":"8","key":"10.1016\/j.cyto.2021.155645_b0380","first-page":"1207","article-title":"Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma","volume":"19","author":"Feghali","year":"1992","journal-title":"J Rheumatol."},{"issue":"6","key":"10.1016\/j.cyto.2021.155645_b0385","first-page":"493","article-title":"Augmented interleukin-6 secretion in collagen-stimulated peripheral blood mononuclear cells from patients with systemic sclerosis","volume":"73","author":"Gurram","year":"1994","journal-title":"Ann Allergy."},{"issue":"2","key":"10.1016\/j.cyto.2021.155645_b0390","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0923-1811(01)00128-1","article-title":"Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis","volume":"27","author":"Sato","year":"2001","journal-title":"J Dermatol Sci."},{"issue":"5","key":"10.1016\/j.cyto.2021.155645_b0395","doi-asserted-by":"crossref","first-page":"R1113","DOI":"10.1186\/ar1790","article-title":"Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis","volume":"7","author":"Rajkumar","year":"2005","journal-title":"Arthritis Res Ther."},{"issue":"2","key":"10.1016\/j.cyto.2021.155645_b0400","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10067-010-1610-4","article-title":"Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis","volume":"30","author":"Hasegawa","year":"2011","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.cyto.2021.155645_b0405","doi-asserted-by":"crossref","unstructured":"Scala E, Pallotta S, Frezzolini A, A et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol. 2004;138(3):540-6.","DOI":"10.1111\/j.1365-2249.2004.02642.x"},{"key":"10.1016\/j.cyto.2021.155645_b0410","doi-asserted-by":"crossref","unstructured":"Khanna D, Denton CP, Lin CJF, vet al, Furst DE. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis. 2018;77(2):212-20.","DOI":"10.1136\/annrheumdis-2017-211682"},{"issue":"10038","key":"10.1016\/j.cyto.2021.155645_b0415","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.cyto.2021.155645_b0420","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.cyto.2021.155645_b0425","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mayocp.2012.10.017","article-title":"Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations","volume":"88","author":"Ernste","year":"2013","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.cyto.2021.155645_b0430","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1749-6632.2009.05119.x","article-title":"Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis","volume":"1184","author":"Mammen","year":"2010","journal-title":"Ann N Y Acad Sci."},{"key":"10.1016\/j.cyto.2021.155645_b0435","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/j.lpm.2010.12.013","article-title":"Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis","volume":"40","author":"Gherardi","year":"2011","journal-title":"Presse Med."},{"key":"10.1016\/j.cyto.2021.155645_b0440","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jneuroim.2006.03.026","article-title":"IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis","volume":"176","author":"Scuderi","year":"2006","journal-title":"J Neuroimmunol."},{"key":"10.1016\/j.cyto.2021.155645_b0445","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/art.24689","article-title":"Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A","volume":"60","author":"Okiyama","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2021.155645_b0450","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2021.155645_b0455","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/art.1780400514","article-title":"Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies","volume":"40","author":"Lundberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cyto.2021.155645_b0460","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/315365","article-title":"Role of the promoter polymorphism IL-6 -174G\/C in dermatomyositis and systemic lupus erythematosus","volume":"2013","author":"Hristova","year":"2013","journal-title":"Biomed Res Int."},{"key":"10.1016\/j.cyto.2021.155645_b0465","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","article-title":"Therapeutic effect of tocilizumab on two patients with polymyositis","volume":"50","author":"Narazaki","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2021.155645_b0470","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT0204354896."},{"issue":"1","key":"10.1016\/j.cyto.2021.155645_b0475","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000235285","article-title":"Possible role of IL-6 in pathogenesis of immune complex-mediated glomerulonephritis in NZB\/W F1 mice: induction of IgG class anti-DNA autoantibody production","volume":"93","author":"Mihara","year":"1990","journal-title":"Int Arch Allergy Appl Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2021.155645_b0480","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/exd.12934","article-title":"Interleukin-6 receptor alpha blockade improves skin lesions in a murine model of systemic lupus erythematosus","volume":"25","author":"Birner","year":"2016","journal-title":"Exp Dermatol."},{"key":"10.1016\/j.cyto.2021.155645_b0485","doi-asserted-by":"crossref","DOI":"10.1111\/cei.13585","article-title":"Arthritis in systemic lupus erythematosus is characterized by local IL-17A and IL-6 expression in synovial fluid","author":"Sippl","year":"2021","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.cyto.2021.155645_b0490","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2249.1991.tb05787.x","article-title":"Urinary IL-6: a marker for mesangial proliferative glomerulonephritis?","volume":"86","author":"Gordon","year":"1991","journal-title":"Clin Exp Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2021.155645_b0495","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/acr2.11217","article-title":"Role of Serum IL-6 in Neuropsychiatric Systemic lupus Erythematosus","volume":"3","author":"Hirohata","year":"2021","journal-title":"ACR Open Rheumatol."},{"issue":"2","key":"10.1016\/j.cyto.2021.155645_b0500","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.cyto.2021.155645_b0505","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/annrheumdis-2012-201310","article-title":"Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus","volume":"72","author":"Shirota","year":"2013","journal-title":"Ann Rheum Dis."},{"issue":"9","key":"10.1016\/j.cyto.2021.155645_b0510","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/art.39722","article-title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis","volume":"68","author":"Rovin","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.cyto.2021.155645_b0515","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/annrheumdis-2016-209668","article-title":"Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial","volume":"76","author":"Wallace","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.cyto.2021.155645_b0520","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren\u2019s syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cyto.2021.155645_b0525","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jaut.2013.11.003","article-title":"Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sj\u00f6gren's syndrome","volume":"51","author":"Gong","year":"2014","journal-title":"J Autoimmun."},{"key":"10.1016\/j.cyto.2021.155645_b0530","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1573397112666160714164149","article-title":"Update on Pathogenesis of Sjogren's Syndrome","volume":"13","author":"Sandhya","year":"2017","journal-title":"Curr Rheumatol Rev."},{"key":"10.1016\/j.cyto.2021.155645_b0535","doi-asserted-by":"crossref","first-page":"R170","DOI":"10.1186\/ar3493","article-title":"Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sj\u00f6gren's syndrome","volume":"13","author":"Yoshimoto","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.cyto.2021.155645_b0540","first-page":"2521","article-title":"Interleukin-6 deficiency corrects nephritis, lymphocyte abnormalities, and secondary Sj\u00f6gren's syndrome features in lupus-prone Sle1.Yaa mice. Arthritis","volume":"66","author":"Maier-Moore","year":"2014","journal-title":"Rheumatol"},{"key":"10.1016\/j.cyto.2021.155645_b0545","first-page":"1089","article-title":"Salivary and serum interleukin 6 in primary Sj\u00f6gren's syndrome","volume":"24","author":"Grisius","year":"1997","journal-title":"J Rheumatol."},{"key":"10.1016\/j.cyto.2021.155645_b0550","unstructured":"Felten R, Devauchelle-Pensec V, Seror R, et al. Interleukin 6 receptor inhibition in primary Sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial. Ann Rheum Dis. 2020:annrheumdis-2020-218467."},{"issue":"9783","key":"10.1016\/j.cyto.2021.155645_b0555","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","volume":"377","author":"Dougados","year":"2011","journal-title":"Spondyloarthritis. Lancet."},{"issue":"3","key":"10.1016\/j.cyto.2021.155645_b0560","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clim.2010.05.003","article-title":"Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitis in Chinese Han population","volume":"136","author":"Chen","year":"2010","journal-title":"Clin Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2021.155645_b0565","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1084\/jem.194.2.189","article-title":"Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation","volume":"194","author":"Ernst","year":"2001","journal-title":"J Exp Med."},{"issue":"2","key":"10.1016\/j.cyto.2021.155645_b0570","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10067-006-0283-5","article-title":"Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis","volume":"26","author":"Bal","year":"2007","journal-title":"Clin Rheumatol."},{"issue":"1","key":"10.1016\/j.cyto.2021.155645_b0575","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molimm.2013.07.016","article-title":"Inflammatory pathways in spondyloarthritis","volume":"57","author":"Hreggvidsdottir","year":"2014","journal-title":"Mol Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2021.155645_b0580","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/BOR.0b013e3283620177","article-title":"Treatment of spondyloarthropathy: the potential for agents other than TNF inhibitors","volume":"25","author":"Her","year":"2013","journal-title":"Curr Opin Rheumatol."},{"issue":"1","key":"10.1016\/j.cyto.2021.155645_b0585","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","article-title":"M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"10.1016\/j.cyto.2021.155645_b0590","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","article-title":"Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)","volume":"74","author":"Sieper","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.cyto.2021.155645_b0595","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cyto.2021.155645_b0600","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.38995","article-title":"Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis","volume":"67","author":"Belasco","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"10.1016\/j.cyto.2021.155645_b0605","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.39700","article-title":"The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cyto.2021.155645_b0610","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s10067-014-2603-5","article-title":"Efficacy of tocilizumab in a patient with refractory psoriatic arthritis","volume":"33","author":"Costa","year":"2014","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.cyto.2021.155645_b0615","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jbspin.2011.06.011","article-title":"Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab","volume":"79","author":"Ogata","year":"2012","journal-title":"J Bone Spine."},{"issue":"6","key":"10.1016\/j.cyto.2021.155645_b0620","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/annrheumdis-2020-217163","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"10.1016\/j.cyto.2021.155645_b0625","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/rheumatology\/kex452","article-title":"Efficacy and safety of biologics targeting interleukin-6, -12\/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis","volume":"57","author":"Wu","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2021.155645_b0630","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/ITT.S280706","article-title":"Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches","volume":"10","author":"Hasan","year":"2021","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.cyto.2021.155645_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.cyto.2021.155645_b0640","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rmv.2141","article-title":"Interleukin-6 in Covid-19: A systematic review and meta-analysis","volume":"30","author":"Coomes","year":"2020","journal-title":"Rev Med Virol."},{"key":"10.1016\/j.cyto.2021.155645_b0645","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern Med."},{"key":"10.1016\/j.cyto.2021.155645_b0650","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Intern Med."},{"key":"10.1016\/j.cyto.2021.155645_b0655","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of Tocilizumab in Patients Hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cyto.2021.155645_b0660","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cyto.2021.155645_b0665","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cyto.2021.155645_b0670","doi-asserted-by":"crossref","unstructured":"Veiga VC, Prats JAGG, Farias DLC, Ret al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021;372:n84.","DOI":"10.1136\/bmj.n84"},{"key":"10.1016\/j.cyto.2021.155645_b0675","doi-asserted-by":"crossref","unstructured":"REMAP-CAP Investigators, Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021;384:1491-1502.","DOI":"10.1056\/NEJMoa2100433"},{"key":"10.1016\/j.cyto.2021.155645_b0680","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637-1645.","DOI":"10.1016\/S0140-6736(21)00676-0"},{"key":"10.1016\/j.cyto.2021.155645_b0685","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm.3260","article-title":"How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy","volume":"19","author":"Schett","year":"2013","journal-title":"Nat Med."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466621002313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466621002313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:03:30Z","timestamp":1760907810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466621002313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":137,"alternative-id":["S1043466621002313"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2021.155645","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An update on the pathogenic role of IL-6 in rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2021.155645","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155645"}}